NEWS
Founded in 2005 in Research Triangle Park, North Carolina, Zylera is focused on developing medications that will treat multiple diseases arising within the inflammation and immunosuppressive pathways. Its near-term pipeline includes products for diabetes, elevated cholesterol, osteoporosis, and osteoarthritis, utilizing proprietary and patented chemical entities designed to restore key metabolic processes. Chief among these is Cytac™, a carbonyl-trapping agent.
The news releases listed below reflect the company’s current news, in order of the most recent release. Please note that we do not intend to update or correct any of these press releases to reflect changes subsequent to the original release.
January 24, 2007: Zylera Pharmaceuticals Announces Availability of RELAMINE for the Treatment of Osteoarthritis
October 30, 2006: Zylera Pharmaceuticals Announces Trade Launch of RELAMINE
October 30, 2006: Zylera Pharmaceuticals Announces Trade Launch of BONISARA for the Treatment of Osteoporosis
October 30, 2006: Zylera Pharmaceuticals Introduces FOLMOR to the Trade
October 18, 2006: Zylera Pharmaceuticals Announces Trade Launch of ZYCOSE for the Treatment of Diabetes
September 12, 2006: Zylera Pharmaceuticals Adds Marketing Strength to Senior Management Team
August 28, 2006: TRx Pharma Finalizes Licensing Agreement with Zylera Pharmaceuticals
Media Contact:
Susan Preston, TRx Pharma
Office: (919) 313-3568